Lilly Diabetes launches mobile application for whose who support people with type 1 diabetes

Eli Lilly and CompanyLilly Diabetes announced the release of a new mobile application designed for caregivers and healthcare providers who support people with type 1 diabetes. The Lilly Glucagon Mobile App is a tool to teach how to use Glucagon for Injection, through simulated practice. Glucagon, 1 mg (1 unit), is indicated to treat severe hypoglycemia (low blood sugar). Severe hypoglycemia due to insulin may result in loss of consciousness (insulin coma). The app is designed to help people be more prepared, and also provide an opportunity to store locations and expiration dates of their Lilly Glucagon Emergency Kits. The Lilly Glucagon Mobile App is now available on the iTunes® store as a free download for iPhone® or iPad® mobile devices.

People with type 1 diabetes who experience severe hypoglycemia during insulin treatment may require glucagon, a hormone produced in the pancreas to raise blood sugar levels.[1] Although Glucagon is rarely needed and only used during a severe hypoglycemic event, individuals in the person's support network, such as family members, teachers, coaches, trusted friends and colleagues, should be trained to give the medicine, which is injected with a syringe. The app can also be used by diabetes educators and school nurses as a teaching tool.

In type 1 diabetes, the body does not produce insulin, a hormone produced by the pancreas in response to an increase in blood sugar, such as after a meal. As many as three million Americans may have type 1 diabetes.[2] Each year more than 15,000 people under age 20 are diagnosed with the disease.[3] Glucagon should not be used in patients who have pheochromocytoma or patients who are allergic to Glucagon. Patients must inform relatives or close friends that if they become unconscious, medical assistance must always be sought. If a patient is unconscious, Glucagon can be given while awaiting medical assistance.

"Lilly Diabetes is committed to developing personalized solutions to help people with diabetes achieve their treatment goals and improve their outcomes," said Matt Caffrey, U.S. Product Brand Director, Marketing Specialty, Lilly Diabetes. "The Lilly Glucagon Mobile App leverages the power and reach of mobile technology, providing another opportunity to support people living with type 1 diabetes. Lilly Diabetes is constantly striving to create new and better tools to support the diabetes community in a variety of ways."

The Lilly Glucagon Mobile App is an interactive tool to help caregivers better understand Glucagon's role in diabetes management. Its purpose is to educate and prepare the caregiver on how to use Glucagon in the event of an emergency. The app was developed with input from healthcare providers and people with diabetes.

The Lilly Glucagon Mobile App includes:

  • Information about severe hypoglycemia and Glucagon
  • Simulated practice demonstrating how to prepare and inject Glucagon
  • Visual and audio emergency instructions
  • Tools to keep track of kit locations and alerts for expiration dates
  • Important safety information

About Lilly Diabetes
Lilly has been a global leader in diabetes care since 1923, when we introduced the world's first commercial insulin. Today we work to meet the diverse needs of people with diabetes through research and collaboration, a broad and growing product portfolio and a continued commitment to providing real solutions - from medicines to support programs and more - to make lives better.

About Eli Lilly and Company
Lilly, a leading innovation-driven corporation, is developing a growing portfolio of pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, IN, Lilly provides answers - through medicines and information - for some of the world's most urgent medical needs.

1. Glucagon. U.S. Library of National Medicine. NIH. Updated September 2010. http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0000691/. Last Accessed May 20, 2012
2. Fact Sheets: General Diabetes Facts. JDRF. Updated December 2011. http://www.jdrf.org/index.cfm?page_id=102586. Last Accessed May 17, 2012.
3. Centers for Disease Control and Prevention. National diabetes fact sheet: national estimates and general information on diabetes and prediabetes in the United States, 2011. Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, 2011. www.cdc.gov/diabetes/pubs/pdf/ndfs_2011.pdf . Last Accessed May 17, 2012.

Most Popular Now

Johnson & Johnson announces advance purchase a…

Janssen Pharmaceutica NV, one of the Janssen Pharmaceutical Companies of Johnson & Johnson (NYSE: JNJ) (the Company), has entered into an agreement with the African Vacci...

Pfizer and BioNTech confirm high efficacy and no s…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced updated topline results from analysis of 927 confirmed symptomatic cases of COVID-19 observed in their pi...

Pfizer-BioNTech announce positive topline results …

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that, in a Phase 3 trial in adolescents 12 to 15 years of age with or without prior evidence of SAR...

GSK to support manufacture of Novavax' COVID-19 va…

GSK has reached an agreement in principle with Novavax and the UK Government Vaccines Taskforce to support manufacturing of up to 60 million doses of Novavax' COVID-19 va...

Valneva reports positive Phase 1/2 data for its in…

Valneva SE, a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical n...

Clinical trial completion rates decline during COV…

Social distancing and lockdowns may have reduced the spread of COVID-19, but researchers from Penn State College of Medicine also report those actions may have affected c...

BioNTech provides update on vaccine production sta…

BioNTech SE today announced that the European Medicines Agency (EMA) approved the manufacturing of the COVID-19 vaccine drug product at the facility in Marburg. As part o...

COVID-19 convalescent plasma with greater antibody…

Convalescent plasma, the use of survivors' antibodies transfused into sick COVID-19 patients is safe and significantly improves clinical outcomes when using high levels o...

Pfizer and BioNTech request regulatory agencies ex…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today requested amendments to the U.S. Emergency Use Authorization (EUA) of the Pfizer-BioNTech vaccine (BNT162b2) ...

Study identifies possible COVID-19 drugs - includi…

A team led by scientists in the Perelman School of Medicine at the University of Pennsylvania has identified nine potential new COVID-19 treatments, including three that ...

COVID-19 causes 'unexpected' cellular response in …

New insights into the immune response to SARS-CoV-2 infections could bring better treatments for COVID-19 cases. An international team of researchers unexpectedly foun...

Undetected coronavirus variant was in at least 15 …

A highly contagious SARS-CoV-2 variant was unknowingly spreading for months in the United States by October 2020, according to a new study from researchers with The Unive...